^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KMT2A-AFF1 fusion

    i
    Other names: AFF1, AF4/FMR2 Family Member 1, ALL1-Fused Gene From Chromosome 4 Protein, Pre-B-Cell Monocytic Leukemia Partner 1, Proto-Oncogene AF4, MLLT2, PBM1, AF4, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax (Drosophila) Homolog); Translocated To 2, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog Drosophila); Translocated To 2, AF4/FMR2 Family Member 1, Protein AF-4, Protein FEL, FEL, KMT2A, Lysine Methyltransferase 2A, Histone-Lysine N-Methyltransferase 2A, CXXC7, TRX1, Myeloid/Ly
    Entrez ID:
    4297; 4299
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    10ms
    Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade. (PubMed, Hemasphere)
    Our findings support that the efficacy of Fc-engineered CD19 antibodies may be substantially enhanced by a combination with CD47 blockade. This suggests that the combination may be a promising therapy option for BCP-ALL, especially in relapsed patients and/or patients refractory to CD19-directed therapy.
    Journal • IO biomarker
    |
    KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    |
    KMT2A rearrangement • MLL rearrangement • CD19 expression • KMT2A-AFF1 fusion
    1year
    Genome editing-induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion. (PubMed, J Clin Invest)
    No abstract available
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1)
    |
    KMT2A-AFF1 fusion
    3years
    The Molecular Landscape of KMT2A-Rearranged Leukemia from Infancy to Adulthood Reveals Age and Leukemia-Specific Mutational Patterns (ASH 2021)
    Primary leukemia cells isolated from moribund mice gave rise to leukemia in sublethally irradiated recipients with reduced disease latency. In conclusion, these results highlight the differential molecular patterns in KMT2A -R leukemia across infancy to adulthood thereby providing novel pathogenetic insight.
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • KMT2A (Lysine Methyltransferase 2A) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • AFF1 (AF4/FMR2 Family Member 1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CSMD3 (CUB And Sushi Multiple Domains 3) • NUTM1 (NUT Midline Carcinoma Family Member 1)
    |
    TP53 mutation • KRAS mutation • NRAS mutation • FLT3 mutation • MLL rearrangement • MLL mutation • KMT2A-AFF1 fusion • MLL fusion • MLL3 mutation